- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02313883
A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis
A Phase I/II Study to Evaluate the Safety, Tolerability and Efficacy of PerioSept® and Scaling and Root Planing in Subjects With Periodontitis
Study Overview
Detailed Description
This trial will follow an adaptive trial design, whereby information regarding PerioSept(r) drug levels will be obtained via a PK trial lead in period (PK Pilot) in a limited number of subjects (up to N=8). This will be followed by the main safety and efficacy trial of PerioSept(r) as an adjunct to scaling and root planing (SRP) in subjects with moderate to severe periodontitis (Main Trial, N=87). The PK Pilot will be an open label PK study. Up to 8 qualifying subjects will receive SRP on Day 1 followed by 3% PerioSept(r) administered in a minimum of 4 qualifying periodontal Study Pockets in at least 2 quadrants with a probing pocket depth (PPD) ≥ 5mm and bleeding on probing (BOP) and at least 20 other qualifying pockets (PPD ≥ 5 mm). The Main Trial will be a multi-center, randomized, blinded, placebo controlled, parallel arm trial of PerioSept(r) (0.3%, 1% or 3%) administered up to three times (over Days 1 and 2, at Weeks 4 and 12) into a minimum of 4 qualifying periodontal Study Pockets in at least 2 quadrants with a PPD ≥ 5mm and BOP following SRP at baseline. All other eligible pockets with a PPD ≥ 5mm will also be treated.
Full mouth SRP will be initiated on Day 1 followed by randomized treatment of that side. If necessary, SRP and randomized treatment may be completed on the other side of the mouth on Day 2. Treated pockets that still have a PPD ≥ 5mm at the 4 and 12 week visits will be retreated with SRP or SRP plus placebo or PS, as randomized. Assessments will be conducted over a 24 week (6 month) period including safety assessments and assessments of dental parameters (PPD, BOP, Plaque index, Gingival Index, Clinical attachment level).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Fullerton, California, United States, 92835
- Regenerative Solutions
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan School of Dentistry
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Texas
-
Houston, Texas, United States, 77063
- Perio Health Professionals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 to 74 years of age, inclusive
- Diagnosed with moderate to severe generalized periodontitis (ADA Classification Case Type III or IV)
- Must have at least 4 qualifying Study Pockets (PPD ≥ 5mm and BOP) in at least 2 quadrants (main trial)
- Subjects must sign informed consent document(s) prior to initiation of any study-specific procedures and treatments
- Agree to utilize study-provided tooth paste and tooth brush and agree to follow their standard oral hygiene routine with limitations noted below from the Day 1 visit through the end of the study
- Sexually active subjects (both men and women) who agree to use acceptable contraceptive methods for the duration of the study
- Able and willing to adhere to the study visit schedule and other protocol requirements
Exclusion Criteria:
- History of and/or known risk of life-threatening anaphylactic reactions to taurolidine, any of the components in the PS drug product, and other drugs or agonists (e.g., penicillin, nuts, insect stings)
- Presence of an acute periodontal abscess
- Known endodontic disease
- Diabetes uncontrolled by medication defined as fasting blood glucose documented at ≥200 mg/dL within 90 days of Day 1
- History of illegal drug or alcohol abuse within the past 12 months and/or testing positive for illegal drugs (including marijuana) at the Screening Visit
- Pregnant or nursing female subjects; women of child-bearing potential must have a negative serum or urine pregnancy test within 30 days and within 24 h prior to all treatment/dosing days
- Use of systemic antibiotics and topically applied oral antibiotics and other antimicrobial agents (e.g., chlorhexidine) during the trial and within 30 days of Day 1.
- An existing condition that may warrant use of antibiotics during the trial (e.g., white blood cell count indicative of ongoing infection noted at Screening Visit, subject with cystic fibrosis or chronic obstructive pulmonary disorder with history of frequent, recurrent lung infections)
- History of and/or testing positive for Hepatitis B or C, Human Immunodeficiency Virus or other immunedeficiency syndrome or positive test for such at Screening Visit
- Use of chewing gum of any kind and dental flossing for one week after all study treatments and use of any other oral dentifrices or oral health agents/treatments other than those provided herein for the study duration
- Use within 30 days prior to Day 1, during trial or a condition for which use is anticipated during trial: topical oral, nasal and systemic corticosteroids, chronic (2 continuous weeks) non-steroidal anti-inflammatory drugs (NSAIDs)
- Use of the agents known to affect periodontal status during the trial and/or use within 30 days prior to Day 1: immunesuppressants, calcium antagonist, phenytoin or anticoagulants
- Heavy smokers/tobacco users are excluded: defined as those smoking ≥ 10 cigarettes or ≥ 4 cigars or ≥ 4 pipes per day
- For non-heavy smokers, smoking ≥ 10 cigarettes or ≥ 4 cigars or ≥ 4 pipes per day is prohibited for the duration of the trial
- Use of electronic/smokeless and herbal cigarettes/pipes and oral smokeless/chewing tobacco within 30 days of Day 1 excluded and all use of these products is prohibited during trial
- Clinically significant (e.g., QTc interval >450 milliseconds) abnormal electrocardiogram (ECG) noted at Screening Visit
- Participation in another clinical study with an investigational agent within 90 days prior to Day 1
- Subjects who received oral health treatments/interventions within 90 days of Day 1, which the investigator believes may interfere with the periodontal parameters to be assessed in this study (e.g., significant dental and/or gum/oral tissue work).
- Subject has a medical and/or dental condition and/or uses medications/supplements which the investigator believes makes him/her unsuitable for participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: SRP only
Scaling and root planing only
|
Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
Other Names:
|
Placebo Comparator: SRP and Placebo
Scaling and root planing followed by placebo drug administration
|
Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
Other Names:
|
Experimental: SRP and 0.3% PerioSept(r)
Scaling and root planing followed by 0.3% PerioSept(r) drug administration
|
Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
Other Names:
|
Experimental: SRP and 1 % PerioSept(r)
Scaling and root planing followed by 1% PerioSept(r) drug administration
|
Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
Other Names:
|
Experimental: SRP and 3% PerioSept(r)
Scaling and root planing followed by 3% PerioSept(r) drug administration
|
Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability:Hematology safety labs, Chem 14, urine analysis, ECG, treatment emergent adverse events, local irritation, patient reported pain, sensisitivity, burning stinging
Time Frame: 6 months
|
Hematology safety labs, Chem 14, urine analysis, ECG, treatment emergent adverse events, local irritation, patient reported pain, sensisitivity, burning stinging
|
6 months
|
Efficacy: Reduction in probing pocket depth (PPD)
Time Frame: 6 months
|
Reduction in probing pocket depth (PPD)
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy REC and CAL: Changes from baseline in Recession (REC)/Clinical attachment level (CAL)
Time Frame: 6 months
|
Changes from baseline in Recession (REC)/Clinical attachment level (CAL)
|
6 months
|
Efficacy BOP: Presence or absence of bleeding on probing (BOP)
Time Frame: 6 months
|
Presence or absence of bleeding on probing (BOP)
|
6 months
|
Efficacy PI: Changes from baseline in Plaque index
Time Frame: 6 months
|
Changes from baseline in Plaque index
|
6 months
|
Efficacy GI: Changes from baseline in Gingival index
Time Frame: 6 months
|
Changes from baseline in Gingival index
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy microbial: Microbial Counts of Periodontal Pathogens
Time Frame: 6 months
|
Microbial Counts of Periodontal Pathogens
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Donald Clem, DDS, Regenerative Solutions
- Principal Investigator: Michael McGuire, DDS, PerioHealth Clinic Houston
- Principal Investigator: Tae-Ju Oh, DDS, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PSPD 1-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontitis
-
Azienda Socio Sanitaria Territoriale degli Spedali...Università degli Studi di FerraraCompletedPeriodontitis, Aggressive | Periodontitis, AdultItaly
-
Panineeya Mahavidyalaya Institute of Dental Sciences...Research Institute for Genetic and Human TherapyUnknownGeneralized Adult Periodontitis
-
Asem Mohammed Kamel AliCompletedMolar-incisor Pattern Grade C Periodontitis ( Localized Aggressive Periodontitis) | Generalized Grade C Periodontitis (Generalized Aggressive Periodontitis)Egypt
-
Columbia UniversityCompletedPeriodontal Diseases | Generalized Moderate Chronic Periodontitis | Generalized Severe Chronic PeriodontitisUnited States
-
Aga Khan UniversityCompletedChronic Apical PeriodontitisPakistan
-
Postgraduate Institute of Dental Sciences RohtakUnknownChronic Apical PeriodontitisIndia
-
University Hospital, Strasbourg, FranceRecruitingPeriodontitis, AdultFrance
-
October University for Modern Sciences and ArtsCompletedPeriodontitis, AdultEgypt
-
Loma Linda UniversityTerminated
-
PiLeJeCompletedProbiotics, PeriodontitisFrance
Clinical Trials on PerioSept(r)
-
Geistlich Pharma AGCompletedPeriodontitisUnited States
-
University of California, Los AngelesUniversity of Colorado, Denver; National Institute of Allergy and Infectious... and other collaboratorsCompletedRNA Virus Infections | Respiratory Tract Infections | Influenza, Human | Orthomyxoviridae Infections | Respiratory Tract Disease | Virus Disease | Physiological Effects of Drugs | VaccinesUnited States
-
Klinikum NürnbergUnknown
-
University of California, Los AngelesNational Institute of Allergy and Infectious Diseases (NIAID)CompletedRespiratory Tract Infections | Influenza | VaccinesUnited States
-
LifeScanCompleted
-
Daping Hospital and the Research Institute of Surgery...Not yet recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedHealthy VolunteersFrance
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruiting
-
University of Colorado, DenverAgency for Healthcare Research and Quality (AHRQ)CompletedImmunization RatesUnited States